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Abbreviations used: 
AE:  adverse event 
ALT:  Alanine aminotransferase 
AP:  alkaline phosphatase 
AST:  Aspartate aminotransferase 
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BUN:  Blood urea nitrogen 
cGMP:  current Good Manufacturing Practice 
CRO:  Contract Research Organization 
CRP:  C reactive protein 
CTGF:  Connective tissue growth factor 
COL1A1: Collagen 1A1 
COL1A2: Collagen 1A2 
COL3A1: Collagen 3A1 
DMSO:  Dimethyl sulfoxide 
ECM:  Extracellular matrix 
LUM:  Lumican 
M-MLV RT: Moloney Murine Leukemia Virus Reverse Transcriptase 
MCHC:  Mean corpuscular hemoglobin concentration 
MCV:  Mean corpuscular volume 
mRNA:  messenger RNA 
NBDS:  Non-bulbar dermal sheath 
PCR:  Polymerase chain reaction 
RBC:  Red blood cell 
RCS-01:  Replicel skin (treatment) version 1 
TGFß1:  Transforming growth factor beta 1 
SAASP:  skin-ageing associated secretory phenotype 
SNK:  Student-Newman-Keuls 




Introduction: Skin ageing involves senescent fibroblast accumulation, disturbance in extracellular 2 
matrix (ECM) homeostasis, and decreased collagen synthesis. 3 
Objective: to assess a cell therapy product for aged skin (RCS-01) consisting of ~25 x 106 cultured, 4 
autologous cells derived from anagen hair follicle non-bulbar dermal sheath (NBDS). 5 
Methods: For each subject in the verum group, four areas of buttock skin were injected intra-6 
dermally 1 or 3 times at monthly intervals with RCS-01, cryomedium, or needle penetration without 7 
injection; in the placebo group RCS-01 was replaced by cryomedium. The primary endpoint was 8 
assessment of local adverse event profiles. As secondary endpoints, expression of genes related to 9 
ECM homeostasis was assessed in biopsies from randomly selected volunteers in the RCS-01 group 10 
taken 4 weeks after the last injection. 11 
Results: Injections were well tolerated with no severe adverse events reported 1 year after first 12 
injection. When compared with placebo treated skin, a single treatment with RCS-01 resulted in a 13 
significant upregulation of TGFß1, CTGF, COL1A1, COL1A2, COL3A1, and lumican mRNA expression.  14 
Limitations: The cohort size was insufficient for dose ranging evaluation and subgroup analyses of 15 
efficacy. 16 
Conclusions: RCS-01 therapy is well tolerated and associated with a gene expression response 17 





There is growing evidence that ageing of human skin is driven by the senescence of fibroblasts 21 
located in the upper dermis. Cells expressing markers of senescence are present at increased 22 
frequencies in aged skin of primates and humans [1, 2]. Primary skin fibroblasts isolated from 23 
intrinsically aged human skin exhibit molecular hallmarks of cellular senescence, including a secretory 24 
factor profile which is indicative of incipient cell senescence [3].This secretory phenotype of ~70 25 
proteins, secreted in an age-dependent manner, are collectively termed the skin-ageing associated 26 
secretory phenotype (SAASP). Functional annotation analysis revealed that these proteins can be 27 
assigned to 14 different biological processes, among which extracellular matrix (ECM) organization 28 
was the most prominent. A detailed enrichment and network analysis using the “Reactome 29 
database” revealed that “ECM organization“, “elastic fiber formation”, “activation of matrix 30 
metalloproteinases” and “collagen degradation” categories had the strongest association with 31 
intrinsic skin ageing. These four biological processes are closely linked to ECM remodelling in general, 32 
and are of obvious relevance for defining the clinical, histological and molecular features of aged 33 
human skin. They are linked to a profound disturbance in collagen homeostasis because of a 34 
decrease in de novo collagen synthesis and an increase in collagen degradation [4]. The secretion of 35 
these proteins by senescent fibroblasts may be of pathogenetic relevance for the ageing process of 36 
human skin and, potentially, modulation of this secretion pattern might alter skin ageing. 37 
The emerging field of regenerative medicine focuses on stem cell, progenitor cell and tissue-based 38 
therapies. It involves exploitation of cells and their proliferative capacity, potential to differentiate, 39 
paracrine signaling activity, and because they can be sourced autologously avoiding implant rejection 40 
or the need for immunosuppressive therapy [5]. 41 
To this end, we developed a cell-therapeutic approach based on the intradermal injection of 42 
autologous, cultured mesenchymal cells, isolated from the non-bulbar dermal sheath (NBDS) of hair 43 
follicles. The NBDS represents a unique source of fibroblasts, which express several proteins that 44 
potentially support ECM maintenance, most notably type 1 collagen [6-8]. Cultured NBDS cells 45 
provide a promising platform to treat intrinsically or extrinsically aged/damaged skin such as fine 46 
wrinkles by implanting UV naïve, collagen-producing NBDS cells directly to the affected area. As a 47 
first clinical step, we conducted a first-in-human clinical trial to determine, as a primary objective, the 48 
safety profile of this cell-therapeutic treatment, as defined by the incidence, causality, severity and 49 
seriousness of adverse events (AEs). In addition, as a secondary objective, we analyzed if and how 50 
this treatment affects gene expression in human skin. We focused on genes, which were previously 51 
found to be associated with skin ageing and linked to proteins, which are part of the SAASP. We 52 
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hypothesised that injecting autologous, cultured NBDS cells would be safe and would modify the 53 
local human skin gene expression profile consistent with increased collagen production and a 54 




Materials and Methods 57 
Study Design and Subjects 58 
This clinical study was conducted at the IUF – Leibniz Research Institute for Environmental Medicine, 59 
Düsseldorf, Germany. It was approved by the ethical committee of the Heinrich Heine University in 60 
Düsseldorf, Germany, (study No MO-LKP-779; ClinicalTrials.gov Identifier: NCT02391935) and 61 
received clearance by the Paul Ehrlich Institute competent authority for cell therapy in Germany. The 62 
study design was a phase-I, randomized, double-blind, placebo controlled, single-centre study. 63 
Inclusion and exclusion criteria were as described (Table SI) A total of 26 subjects were screened, of 64 
which 21 were randomized and 17 completed the study protocol (demographic data in Table SII). 65 
Treatments 66 
The study was initiated on October 06th 2015 and the last study visit was conducted on May 16th, 67 
2017. The study included a total of 14 visits, i.e. 3 screening visits and 11 visits during the treatment 68 
and observation period. At visit 1, visit 3 and visit 5 (Fig. 1, A), study subjects were injected intra-69 
dermally with a cell therapy product (RCS-01; verum) manufactured from the subject’s own 70 
(autologous) NBDS cells isolated from hair follicles, or they received the respective placebo. For this, 71 
a punch biopsy was taken at IUF from the back of the subject’s scalp (occiput) at the second 72 
screening visit (visit S2; Fig. 1, A). The tissue sample was then transferred to biopsy media and 73 
subsequently shipped to the cGMP manufacturer of the RCS-01 product (Innovacell Biotechnologie 74 
AG, Innsbruck, Austria). At the manufacturing site, the tissue biopsy was dissected to isolate hair 75 
follicle non-bulbar dermal sheaths, which were then put into culture during which the NBDS cells 76 
were replicated to achieve 25.0 106 ± 3.0 x 106 NBDS cells per individual batch. The NBDS cells were 77 
then suspended in cryomedium composed of Ringer’s lactate containing 2% human serum albumin 78 
and 5% DMSO. RCS-01, as well as placebo, were supplied by the manufacturer in coded, single-dose 79 
vials. Placebo vials contained cryomedium only. Vials containing RCS-01 or placebo were then 80 
shipped from the manufacturing site to the study site and kept below -130°C until administration. At 81 
the study site, verum and placebo products were injected in a volume of 1.0 ml evenly distributed in 82 
six injections throughout the approximately 2 cm2 area. A syringe holder controlled depth, angle and 83 
volume of the injections into the dermis of the buttock. Sham injections involved only needle 84 
penetration with no fluid injected. (Figs 1-2).  85 
Randomization and Masking 86 
Randomization of subjects to the two treatment groups (RCS-01 group and placebo group) in a 4:1 87 
ratio and the two post-treatment biopsy groups (visit 7 biopsy group and visit 9 biopsy group; Fig. 1, 88 
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B) used two separate randomization lists, which were computer generated by Pharmalog Institut für 89 
Klinische Forschung GmbH, Munich, Germany, which served as the CRO in this study. The vehicle 90 
treated area in the group of RCS-01 receiving volunteers served as an intraindividual control for 91 
evaluation of local AEs as compared to the verum treated areas in the same volunteer, while the 92 
smaller group only receiving placebo served as a control for systemic AEs. 93 
The randomization ratio used for allocation to one of the injections sites of the four (RCS-group) / 94 
two (placebo group) treatment patterns was 1:1:1:1 and 1:1, respectively (Fig. 2). As RCS-01 and 95 
placebo were visually different, an unblinded study team member not involved in any post 96 
administration evaluations performed all injections, including sham injections, at visits 1, 3 and 5. 97 
Related information was kept separately from other records and was accessible only to the 98 
unblinded study team member. 99 
Safety Parameters 100 
Clinical safety assessments included height, body weight, vital signs, an abbreviated clinical 101 
examination, serology laboratory assessments according to the exclusion criteria, safety laboratory 102 
assessments including haematology (RBC, haematocrit, MCV, MCHC, reticulocytes, WBC with 103 
differential, platelet count), biochemistry (sodium, potassium, creatinine, total protein, AP, total 104 
cholesterol, ALT, AST, BUN, CRP), and dipstick urinalysis (protein, glucose, ketones, bilirubin, blood, 105 
urobilinogen, pH, specific gravity, nitrite, hemoglobin and leukocytes), investigator assessment of the 106 
treatment evaluation sites for local intolerance (solicited local adverse events: erythema, bruising / 107 
haemorrhage, pyoderma / infection, eczema, granuloma / papules / nodules, hypertrichosis / hair 108 
density, hypopigmentation, hyperpigmentation, scar), and adverse events (AEs). A detailed definition 109 
of the AEs is given in Table 1. In addition, histopathological evaluation of treatment sites was 110 
performed on biopsies obtained at visit 9 (Fig. 1, A). 111 
Efficacy Parameters 112 
Gene expression studies used total RNA which was extracted from punch biopsies obtained from all 113 
four treatment sites at visit 7 (Fig. 1, A) as previously described [9-12]. Frozen biopsies were 114 
disrupted in lysis buffer from an RNA isolation kit (Peq-Gold Total RNA Kit (Peqlab, Erlangen, 115 
Germany) using a Mixer Mill MM300 (Retsch, Haan, Germany) three times for 3 minutes with 30Hz. 116 
Isolated RNA was photometrically quantified and 50 ng total RNA was used for cDNA synthesis with 117 
M-MLV reverse transcriptase (Life Technologies, Karlsruhe, Germany). An aliquot was used for 118 
pipetting PCR reactions with ABsolute QPCR SYBR Green Mix (Thermo Fisher Scientific, St. Leon, 119 
Germany) with the help of an epMotion 5070 pipetting device (Eppendorf, Wesseling-Berzdorf). PCR 120 
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reactions, using primer sequences as described (Supplemental Table SIII), were performed in a 121 
CFX384 Real-Time PCR Detection System (Bio-Rad Laboratories GmbH, München, Germany) after 15 122 
minutes at 94° C for activation of hot start Taq polymerase. Cycles consisted of 20 seconds 123 
denaturation (95° C), 20 seconds annealing (55° C) and 20 seconds extension (72° C). For comparison 124 
of relative gene expression in real time PCR the 2(-C(T)) method was used [13]. 125 
Pro-collagen ELISA Assay 126 
Cultures of NBDS cells were examined for expression of pro-collagen (n=5). Briefly, NBDS cells were 127 
cultured using the clinical trial protocols. Cells were plated post collection at the end of passage 4 of 128 
primary culture (8 x 104 cells per well in a 6-well plate; Corning, Tewksbury, MA) in duplicates; 129 
equivalent to the point at which cells are injected in the clinical trial. Culture supernatants were 130 
sampled at 0, 3, and 6 hours post plating, and the concentration of pro-collagen type I was quantified 131 
according to manufacturer’s instructions (Procollagen Type I C-Peptide EIA Kit, Takara-Bio, Mountain 132 
View, CA). 133 
Statistical Analysis of Gene Expression 134 
Data are given as x-fold induction as compared to a placebo control as median [25% to 75% 135 
percentiles]. Statistical evaluation and graphical presentation was performed with SigmaPlot 12.3 136 
(Systat Software GmbH, Erkrath, Germany). Normality of the data was tested using Shapiro-Wilk. For 137 
comparison of significant differences, Kruskal-Wallis one-way analysis or variance on ranks was 138 
employed. As post hoc analysis, the SNK test was used. A probability level of p<0.05 was considered 139 





A total of 26 subjects (Supplemental Table SII) were screened at screening visit 1. From these, five 143 
were not randomized due to the presence of exclusion criteria (n=3), withdrawal of consent (n=1) or 144 
onset of an adverse event (n=1) that prevented the subject returning for screening visit 2. The 145 
remaining 21 subjects had a scalp biopsy and were randomized to the two treatment groups at 146 
screening visit 2 (Fig. 2). From these, 4 subjects, which had been randomized to the verum treatment 147 
group, did not receive any intradermal injections of study products because NBDS cell cultivation was 148 
not successful due to poor biopsy quality. 149 
Of the 17 subjects (15 females and 2 males, mean age of 55.1 years) which completed the study, 13 150 
(76.5%) were in the RCS-01 group (Fig. 2), i.e. they received intradermal injections of RCS-01 and 151 
placebo and sham injections, whereas 4 subjects (23.5 %) were in the placebo group (Fig. 2), i.e. they 152 
received intradermal injections of placebo and sham injections, but not RCS-01 injections. This 153 
approximately reflects the intended ratio of 4:1. All 17 subjects also completed the 44-weeks post 154 
injection follow-up period. 155 
The safety data of the 13 individuals in the RCS-01 subgroup demonstrated a good local and systemic 156 
safety profile of RCS-01 injections up to 1 year after single and triple intradermal injections. Serious 157 
local or systemic AEs did not occur. There was no evidence of systemic toxicity. No clinically relevant 158 
changes were observed in mean values of systolic / diastolic blood pressure, pulse rate, body 159 
temperature and body weight of the treated subjects. There were neither clinically significant 160 
abnormal laboratory test results shortly after study treatment, nor any clinically relevant changes 161 
during the course of the study. Fourteen out of 17 treated subjects reported at least 1 local and / or 162 
systemic AE (Table 1). One out of 13 subjects treated in the RCS-01 group and one out of 4 subjects 163 
treated in the Placebo group experienced at least 1 systemic AE after the first treatment (treatment-164 
emergent AEs). All systemic AEs were considered unrelated or unlikely related to the study treatment 165 
and had resolved by the end of the observation period. 166 
Ten subjects out of 13 in the RCS-01 group, and all 4 subjects in the placebo group, presented with at 167 
least one solicited local AE of mild to moderate intensity, which were all transient in nature. Mild 168 
bruising (haemorrhage) at the injection site was the most common local AE with a similar occurrence 169 
after intradermal administration of RCS-01 and placebo and sham injections. 170 
Repeated intradermal injection of RCS-01 was associated with a higher occurrence of granuloma, 171 
papules or nodules compared to control injection of cryomedium (placebo). Hyperpigmentation, 172 
eczema and erythema was observed rarely and showed no increased occurrence after repeated 173 
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treatment with RCS-01 and placebo. There were no signs of pyoderma (infection), hypertrichosis and 174 
hypopigmentation at the injection sites of RCS-01 or placebo. In addition, histopathological 175 
assessment of 32 treatment sites from 8 subjects, which were biopsied 4 months after the last 176 
injection, revealed no abnormalities or structural changes (data not shown). 177 
In terms of pro-collagen type C peptide expression post production (after passage 4), NBDS cells 178 
exhibited relatively consistent levels of pro-collagen expression (mean at 6 hrs., 57ng /ml/8 x 104 179 
cells; range, 42ng – 69ng) in culture supernatants (Fig. 3). 180 
Gene expression analysis was performed using biopsies obtained from 7 subjects of the RCS-01 group 181 
at visit 7 (Fig. 1, A), i.e. 1 month after the last injections with RCS-01 and placebo. A single injection of 182 
RCS-01 caused a significant increase in mRNA expression of all genes, as compared with mRNA 183 
expression of these genes in placebo treated skin (Supplemental Table SIV). Notably, although we did 184 
not assess the impact on clinical signs of aging such as wrinkle formation, some of the strongest 185 
responses were observed for TGFß1, and also for genes involved in de novo collagen synthesis such 186 
as COL1A1, COL1A2 and COL3A1 (Fig. 4). Increased gene expression was also observed when RCS-01 187 
was injected 3 times, but overall the response was weaker than that observed after single treatments 188 





In this study we show for the first time that single and repeated injections of NBDS-derived 192 
autologous cells into the dermis of human buttock skin are well tolerated and do not cause systemic 193 
or local adverse reactions for a period of up to 1 year after the first injection. We also provide 194 
evidence that this cell-therapeutic approach alters the transcriptional expression profile of genes, 195 
which are involved in ECM homeostasis. Specifically, we have found that in comparison to placebo 196 
treated skin areas, injection of NBDS-derived fibroblasts induces the expression of TGFß1, CTGF, 197 
COL1A1, COL1A2, COL3A1 and lumican. 198 
These genes encode for proteins which are important for ECM homeostasis, thought to be of 199 
pathogenetic relevance for skin ageing, where levels of types I and III collagen precursors and 200 
crosslinks are reduced [14]. Accordingly, TGFß1 is the major profibrotic cytokine and, together with 201 
CTGF, synergistically stimulates type 1 procollagen synthesis in adult human fibroblasts [15]. Also, 202 
COL1A1 and COL1A2 are crucial for de novo synthesis of type 1 collagen chains, which are markedly 203 
decreased in aged human skin [14-16]. Lumican belongs to small leucine-rich proteoglycan family and 204 
is involved in collagen fibril formation in skin [17]. Upon UV irradiation, lumican expression is 205 
decreased in human dermal fibroblasts, which might contribute to downregulation of procollagen I in 206 
UV-irradiated skin [18]. 207 
The present observation that injection of NBDS-derived cells is associated with an increased 208 
transcriptional expression of these genes indicates the possibility that cell therapy with RCS-01 might 209 
be able to ameliorate the clinical signs of skin ageing, such as wrinkles. This assumption is in line with 210 
observations that increased expression of collagen type 1 and type 3 is a prerequisite for wrinkle 211 
reduction caused by retinol [19]. We therefore believe that our observations warrant corresponding 212 
phase -2 studies to directly assess this possibility. Insufficient cohort size for dose ranging evaluation 213 
and subgroup analyses of efficacy was the primary limitation of the current study. Future clinical 214 
studies will explore dose responses, the possibility of single and multiple injections involving smaller 215 
doses or spaced over longer periods. 216 
The present study does not provide any information about the mechanism underlying RCS-01-217 
induced gene expression in human skin. Since RCS-01 treatment increased the expression of genes, 218 
which are primarily expressed by dermal fibroblasts, we believe that RCS-01 mainly acts at the level 219 
of the dermis. It should be noted, however, that in this study full thickness punch biopsies were 220 
analyzed for gene expression without further separation into dermal and epidermal compartments. 221 
We can therefore not rule out that RCS-01 can also have effects on epidermal cells. Increased mRNA 222 
expression was not observed in skin areas, which were injected with placebo only, or sham injected, 223 
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indicating that modulation of gene expression was not due to the presence of the cryomedium or to 224 
mechanical effects caused by the injection procedure per se, but instead required the intradermal 225 
presence of the injected NBDS-derived fibroblasts. Further studies will have to clarify how these 226 
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Fig. 1. A summarised schedule of assessments (A) and an example treatment pattern for the RCS-01 
and Placebo treatment group (B): Each subject had 4 treatment sites on the buttock (two on each 
buttock), which were identified by a tattoo. On visit 1, subjects from the RCS treatment group 
17 
 
received either placebo (cryomedium), RCS-01, or sham injections (needle penetration without 
injection of any fluid) according to a randomisation schedule. After 4 weeks, subjects returned and 
received the same treatment in the same pattern as before. Treatment evaluation sites treated with 
two doses of placebo or RCS-01 at visits 1 and 3 received a third injection of RCS-01 or placebo. The 
other two treatment evaluation sites previously receiving sham injections randomly received 
injections of either RCS-01 or placebo. For subjects in the Placebo group, the treatment pattern was 
similar except that RCS-01 was replaced by placebo. 
 
 




Fig. 3. Concentration of pro-collagen Type I C-peptide in culture supernatants from 8x104 non-
bulbar dermal sheath cells (NBDS) processed and cultured from 5 individuals, and mean 
concentration for NBDS cells. 
 
Fig. 4. Upregulation of mRNA levels for dermal markers after single or triple treatment with RCS01 
as compared to a single placebo treatment. Given are box plots of n=9, error bars reflect 95% and 5% 
percentiles. Dashed line indicates placebo treated level set arbitrarily equal to 1. *p<0.05 indicated 




Table 1. Overview of subjects with adverse events 
Systemic / local AEs RCS-01 Subgroup  
(N=13, 100%) 




Total subjects with AEs 10 (76.9%) 4 (100.0%) 14 (82.4%) 
Subjects with at least one local AE 
         Solicited local AEs 










Subjects with at least one systemic AE 
         Onset before first treatment 
         (Visit S1 - Visit 1) 
         Onset after first treatment 













Subjects with at least one serious AE 0 0 0 
 






 Hypertrichosis/hair density 
 Hypopigmentation 
 Hyperpigmentation 
 Scarring 
 
